Burning Rock Biotech
85 hedge funds and large institutions have $794M invested in Burning Rock Biotech in 2021 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 9 closing their positions.
344% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 9
57% more funds holding
Funds holding: 54 → 85 (+31)
25% more capital invested
Capital invested by funds: $635M → $794M (+$159M)
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
0.39% more ownership
Funds ownership: 2.7% → 3.09% (+0.39%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$55.6M |
| 2 |
BlackRock
New York
|
+$51.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.3M |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
+$11.6M |
| 5 |
MICM
Matthews International Capital Management
San Francisco,
California
|
+$9.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$22.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.6M |
| 3 |
Goldman Sachs
New York
|
-$18M |
| 4 |
Jennison Associates
New York
|
-$6.99M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.95M |
BNR Hedge Fund Activity: Q2 2021 in Review
85 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q2 2021, worth a combined $794M — up 25% from $635M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new BNR positions and 9 closed out — a net gain of 31 holders — while 19 added to existing stakes and 16 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $55.6M. The largest seller was Casdin Capital, exiting entirely with an estimated $22.8M sold.
- 85 institutional investors held Burning Rock Biotech (BNR) as of Q2 2021, up from 54 in Q1 2021.
- Funds reported $794M of Burning Rock Biotech stock for Q2 2021, up 25% quarter-over-quarter.
- 40 funds opened new Burning Rock Biotech positions in Q2 2021 and 9 closed out, a net change of +31 holders.
- The largest Burning Rock Biotech buyer in Q2 2021 was Baillie Gifford & Co, an estimated $55.6M added.
- The largest Burning Rock Biotech seller in Q2 2021 was Casdin Capital, an estimated $22.8M sold.
Based on aggregated 13F filings for Q2 2021.